Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company has submitted a New Drug Application to
the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir
(100mg/50mg), an investigational once-daily, single tablet combination
therapy for the treatment of adult patients with chronic hepatitis C
genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the
FDA will determine whether it will accept for review Merck's application
as filed.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 908-740-1871orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Merck | New Drug Applications | Pharmaceuticals